NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -36.54% | -20.20% | -46.68% | -156.73% | -974.83% |
| Total Depreciation and Amortization | 130.61% | 228.95% | 1,486.36% | 2,955.56% | 276.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 288.61% | 73.78% | 53.65% | 101.26% | 30.52% |
| Change in Net Operating Assets | -657.01% | -130.72% | -119.45% | -106.85% | 856.32% |
| Cash from Operations | -12.28% | -90.50% | -2,703.75% | -13,603.05% | -2,617.03% |
| Capital Expenditure | -2,700.00% | -414.94% | -162.34% | -77.01% | 89.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -261,766.67% | -414.94% | -162.34% | -77.01% | 89.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9,546.89% | 59.56% | -0.61% | 1.39% | -97.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 82.22% | 91.11% | 91.11% | -- |
| Cash from Financing | 7,300.21% | 22.36% | -37.05% | -42.92% | -97.78% |
| Foreign Exchange rate Adjustments | -234.64% | 257.44% | -95.96% | -106.58% | -6.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 438.86% | -37.11% | -95.64% | -89.08% | -130.91% |